BOYD MATTHEW ROSS enters ENGENE THERAPEUTICS INC. with 7.50K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 7/14/2025ACC: 0000929638-25-002585
Officer· Chief Regulatory Officer
Since Jan 2026
7.50K
Baseline shares
100% direct
7.50K
Direct ownership
1 position
119K
Derivative underlying
2 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Shares
DirectShares owned7.50K
Total
7.50K direct7.50K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 7.50K | Direct |
| Total | 7.50K | 7.50K direct |
Derivative Holdings2
Stock Option (Right to Buy)
DirectUnderlying security
Common Shares
Underlying shares
68K
Shares owned
N/A
Exercise price
6.6
Expiration
—
Exercise window
—
Stock Option (Right to Buy)
DirectUnderlying security
Common Shares
Underlying shares
51K
Shares owned
N/A
Exercise price
7.39
Expiration
—
Exercise window
—
Total
Underlying
119K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Shares | 6.6 | — | — | 68K | N/A |
| Stock Option (Right to Buy) Direct | Common Shares | 7.39 | — | — | 51K | N/A |
| Total | 119K | 0.00 | ||||